Laboratory Corporation of America® Holdings (LabCorp®) announced that it has introduced its MGMT gene methylation assay using Methylation-Specific PCR technology licensed from OncoMethylome Sciences (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA).
Methylation of the MGMT gene promoter has been shown to be a common event in brain cancers and predictive of response to some therapies. “DNA methylation is a key gene regulation mechanism in cancer. Lab tests to determine methylation status of specific genes in various cancers are important and differentiating additions to our menu of oncology services,” commented Dr. Andrew J. Conrad, Chief Scientist and Global Head of Clinical Trials for LabCorp. "The addition of this test to our menu of oncology services continues our leadership in personalized medicine and gives oncologists a new tool to help guide patient care."
LabCorp’s Esoterix Clinical Trials Services Division was also selected by OncoMethylome as one of its preferred sub-contractors for MGMT methylation testing services for clinical trials.